Login to Your Account

AFFINITY fizzle bums hizzle post-SYNERGY, Oncogenex hopeful ENSPIRIT

By Randy Osborne
Staff Writer

Tuesday, August 16, 2016

With the second phase III failure of antisense oligonucleotide custirsen in CRPC, Oncogenex Pharmaceuticals Inc. investors have turned their eyes to NSCLC, where the clusterin inhibitor is undergoing late-stage tests in combination with docetaxel.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription